Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma

NCT05109052 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped no accrual of eligible participants

Conditions

Hepatocellular Carcinoma
Cancer of Liver

Interventions

DRUG: PXS-5505 and Atezolizumab and Bevacizumab

Sponsor

University of Rochester